Platelet‑Rich Plasma (PRP) for Joint Pain and Hair Loss: An Evidence‑Based Review

Platelet‑rich plasma (PRP) has become one of the most widely used regenerative therapies in orthopedic and aesthetic medicine. As clinicians and patients seek non‑pharmacologic, minimally invasive options for joint pain and hair loss, PRP offers a biologically plausible and increasingly well‑studied intervention. Yet, its use remains heterogeneous, and regulatory oversight is often misunderstood. This review summarizes the current evidence, FDA considerations, benefits, risks, and limitations of PRP for joint therapy and hair restoration.

What PRP Is — and How It Works

PRP is an autologous preparation of plasma containing a higher‑than‑baseline concentration of platelets. Platelets release growth factors and cytokines that support tissue repair, angiogenesis, and modulation of inflammation. PRP is produced by drawing a patient’s blood, centrifuging it to isolate platelets, and injecting the concentrated product into the target tissue.

PRP for Joint Pain

Evidence Summary

Osteoarthritis & Tendinopathy

Multiple orthopedic studies show PRP can reduce pain and improve function in knee osteoarthritis, outperforming steroid injections, hyaluronic acid, NSAIDs, exercise, ozone, prolotherapy, and bone marrow aspirate concentrate.

Meta‑analyses also demonstrate improved outcomes in rotator cuff tendinopathy and lateral epicondylitis, including reduced re‑tear rates and better pain/function scores compared with standard care.

Mechanism

PRP increases platelet‑derived growth factors at the injury site, recruits stem cells, and accelerates healing of ligaments, tendons, and cartilage.

Benefits of PRP Joint Therapy

• Autologous & low‑risk: Uses the patient’s own blood, minimizing allergic reactions.

• Improved pain & function: Demonstrated superiority over several standard injections for knee OA.

• Accelerated soft‑tissue injury-related function: Particularly effective for tendon and ligament injuries.

• May delay surgery: Some patients experience relief lasting up to one year.

Risks & Limitations

• Post‑injection soreness is common but usually mild.

• Technique variability: PRP dose, platelet concentration, and centrifuge protocols differ widely across clinics, affecting outcomes.

• Not universally effective: Severe OA (grade 4) or advanced structural damage may respond less robustly.

• Lack of standardization: No universal protocol for number of injections or platelet thresholds.

FDA Status for Joint PRP

Evidence Summary

Androgenetic Alopecia (AGA)

Systematic reviews and meta‑analyses show PRP significantly increases hair density compared with placebo, both as monotherapy and as an adjunct.

• Stand‑alone PRP: Mean density increase of 25.39 hairs/cm².

• Combination therapy: Mean density increase of 34.38 hairs/cm².

PRP also improves follicle survival and early regrowth when used with hair transplantation.

Emerging Innovations

Photothermal conditioning of PRP may enhance growth factor release and exosome production, potentially improving hair regeneration, though protocols remain unstandardized.

Benefits of PRP Hair Therapy

• Non‑surgical & autologous: No foreign substances; low risk of allergic reactions.

• Improves hair density & thickness: Strong evidence for AGA in both men and women.

• Minimal downtime: Redness/tenderness typically resolves within 24–48 hours.

• Adjunct to hair transplant: Enhances graft survival and early growth.

Risks & Limitations

• Injection discomfort, temporary redness, or swelling.

• Variable response: Works best in early‑to‑moderate hair loss; less effective in advanced follicle miniaturization.

• Protocol inconsistency: No standardized dosing, frequency, or platelet concentration.

Not a cure for alopecia areata or scarring alopecias, though some studies show partial benefit.

FDA Status for Hair PRP

As with joint PRP, PRP for hair restoration is not FDA‑approved as a treatment for alopecia. The FDA regulates PRP preparation devices, but the injection of autologous PRP is permitted under medical practice.

Clinical Bottom Line

PRP is a promising regenerative therapy with growing evidence for joint pain and hair loss, especially androgenetic alopecia. Benefits include improved pain, function, hair density, and graft survival, with low risk due to its autologous nature. However, PRP is limited by lack of standardization, variable patient response, and absence of FDA approval for specific indications.

Clinicians should use evidence‑based protocols, disclose limitations, and ensure patients understand realistic expectations.

References

• Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid for knee osteoarthritis: A randomized controlled trial. Am J Sports Med. 2015;43(7):1575‑1582.

• Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double-blind randomized trial. Am J Sports Med. 2013;41(2):356‑364.

• Fitzpatrick J, Bulsara M, Zheng MH. The effectiveness of platelet-rich plasma in the treatment of tendinopathy: A meta-analysis of randomized controlled clinical trials. Am J Sports Med. 2017;45(1):226‑233.

• Mautner K, Malanga GA, Colberg RE, et al. A systematic review of platelet-rich plasma for chronic tendinopathy. PM&R. 2013;5(6):514‑523.

• Gentile P, Garcovich S. Autologous platelet-rich plasma for the treatment of androgenetic alopecia: A systematic review and meta-analysis. Aesthetic Plast Surg. 2020;44(3):1043‑1054.

• Gupta AK, Carviel JL. A systematic review of platelet-rich plasma for androgenetic alopecia. J Dermatolog Treat. 2022;33(1):49‑56.

• Alves R, Grimalt R. Platelet-rich plasma in androgenetic alopecia: A randomized, placebo-controlled trial. Dermatol Surg. 2016;42(4):491‑497.

• Turner L, Knoepfler P. Selling stem cells in the USA: Assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154‑157.

• Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell–based interventions: A call to action. Sci Transl Med. 2017;9(397):eaag0426.

• Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med. 2017;376(11):1047‑1053.

• Bauer G, Elsallab M, Abou‑El‑Enein M. Concise review: A comprehensive analysis of reported adverse events in patients receiving unproven stem cell interventions. Stem Cells Transl Med. 2018;7(9):676‑685.

• Marks PW, Witten CM, Califf RM. Clarifying stem‑cell therapy regulations. N Engl J Med. 2017;376(11):1007‑1009.

• Turner L. The US direct‑to‑consumer stem cell industry and FDA enforcement: An update. Regen Med. 2019;14(9):841‑847.

• Master Z, Resnik DB, Caulfield T. Stem‑cell tourism and scientific responsibility. EMBO Rep. 2011;12(10):992‑996.

• O’Connor D, Caplan A. Unproven stem cell therapies: The ethics of marketing and clinical use. JAMA. 2019;321(16):1565‑1566.

• Wilson JM, Flotte TR. Regulating unproven stem cell interventions. Mol Ther. 2020;28(2):378‑380.